Chromosomal Heterogeneity and Enrichment of Mitotic Regulatory Programs Reveal a Therapeutic Vulnerability in Cytarabine-Resistant FLT3-ITD AML.

Jui-Hung Yen, Zi-An Chen, Yu-Xuan Lin, Hui-Yu Jiang, Liang-In Lin, Chi-Cheng Li, Pei-Yi Chen

Abstract read

In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jui-Hung YenDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 970374, Taiwan.ORCID 0000-0003-2551-350X

Zi-An ChenDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 970374, Taiwan.ORCID 0009-0008-6967-8094

Yu-Xuan LinDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 970374, Taiwan.

Hui-Yu JiangLaboratory of Medical Genetics, Genetic Counseling Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970374, Taiwan.

Liang-In LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 10048, Taiwan.ORCID 0000-0002-3561-1093

Chi-Cheng LiDivision of Hematology-Oncology, Department of Internal Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970374, Taiwan.

Pei-Yi ChenDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 970374, Taiwan.ORCID 0000-0003-4270-7031

Funding

Buddhist Tzu Chi Medical Foundation TCMMP114-03-03Hualien Tzu Chi Hospital TCRD-115-042National Science and Technology Council NSTC 112-2320-B-320-002-MY3National Science and Technology Council NSTC 113-2320-B-303-002

6 · The paper itself

Abstract

Cytarabine is a cornerstone of acute myeloid leukemia (AML) therapy; however, acquired resistance remains a major clinical challenge. FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), a common genetic alteration in AML, is associated with high relapse rates and poor outcomes. Here, we investigated the cellular and molecular mechanisms of acquired cytarabine resistance in FLT3-ITD AML. Cytarabine-resistant MV4-11-CR and MOLM-13-CR cells were generated from parental MV4-11 and MOLM-13 cells, respectively, by stepwise drug selection. Both models exhibited markedly elevated cytarabine IC

Indexed as

AMLchromosomal heterogeneitycytarabineFLT3-ITDmitotic spindle

Identifiers

PMID42793322

DOI10.3390/cimb48090966

PMCPMC13605166

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.